Enterprise Value

0.00

Cash

52.2M

Avg Qtr Burn

N/A

Short % of Float

3.75%

Insider Ownership

10.35%

Institutional Own.

0.49%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Lenzilumab Details
Graft-versus-host disease

Phase 2/3

Data readout

Lenzilumab Details
Leukemia, Chronic myelomonocytic leukemia

Phase 2/3

Interim update

Ifabotuzumab (iFab) Details
Glioblastoma, Cancer

Phase 1b

Initiation

Failed

Discontinued

Lenzilumab Details
Cancer, Non-Hodgkin lymphoma

Failed

Discontinued

Lenzilumab with CAR-T Details
B-cell malignancies, Cancer

Failed

Discontinued

Lenzilumab Details
Respiratory conditions, Asthma

Failed

Discontinued